Previous Close | 4.6800 |
Open | 4.6400 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's Range | 4.6400 - 4.6400 |
52 Week Range | 3.2000 - 7.9000 |
Volume | |
Avg. Volume | 0 |
Market Cap | 280.334M |
Beta (5Y Monthly) | 0.88 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Sutro Biopharma, Inc. ( NASDAQ:STRO ) shareholders should be happy to see the share price up 15% in the last month...
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 8.43% and 11.65%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Sutro Biopharma, Inc. (STRO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
IDEAYA Biosciences, Inc. (IDYA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sutro Biopharma, Inc. (STRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
With a price-to-sales (or "P/S") ratio of 3.9x Sutro Biopharma, Inc. ( NASDAQ:STRO ) may be sending very bullish...
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 4.69% and 24.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Looking at Sutro Biopharma, Inc.'s ( NASDAQ:STRO ) insider transactions over the last year, we can see that insiders...
In this article we are going to estimate the intrinsic value of Sutro Biopharma, Inc. ( NASDAQ:STRO ) by estimating the...
If you want to know who really controls Sutro Biopharma, Inc. ( NASDAQ:STRO ), then you'll have to look at the makeup...
While it may not be enough for some shareholders, we think it is good to see the Sutro Biopharma, Inc. ( NASDAQ:STRO...
Shareholders in Sutro Biopharma, Inc. ( NASDAQ:STRO ) may be thrilled to learn that the analysts have just delivered a...
The average of price targets set by Wall Street analysts indicates a potential upside of 213.8% in Sutro Biopharma, Inc. (STRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Sutro Biopharma ( NASDAQ:STRO ) Third Quarter 2022 Results Key Financial Results Revenue: US$25.1m (up 195% from 3Q...
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of -146.67% and 121.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Sutro Biopharma, Inc. (STRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The average of price targets set by Wall Street analysts indicates a potential upside of 326% in Sutro Biopharma, Inc. (STRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
The average of price targets set by Wall Street analysts indicates a potential upside of 293.4% in Sutro Biopharma, Inc. (STRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
From what we can see, insiders were net buyers in Sutro Biopharma, Inc.'s ( NASDAQ:STRO ) during the past 12 months...
bluebird's (BLUE) Syskona (eli-cel) gets FDA approval for early, active cerebral adrenoleukodystrophy (CALD) in patients less than 18 years of age.
The average of price targets set by Wall Street analysts indicates a potential upside of 288.1% in Sutro Biopharma, Inc. (STRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
The average of price targets set by Wall Street analysts indicates a potential upside of 294.8% in Sutro Biopharma, Inc. (STRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Celebrations may be in order for Sutro Biopharma, Inc. ( NASDAQ:STRO ) shareholders, with the analysts delivering a...
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 25.68% and 105.92%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...